Vibozilimod - Sun Pharmaceutical Industries
Alternative Names: SCD-044Latest Information Update: 28 Apr 2022
At a glance
- Originator Bioprojet; Sun Pharma Advanced Research Company
- Developer Bioprojet; Sun Pharma Advanced Research Company; Sun Pharmaceutical Industries
- Class Antipsoriatics; Carboxylic acids; Chlorobenzenes; Oxadiazoles; Piperidines; Skin disorder therapies; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Plaque psoriasis
- No development reported Autoimmune disorders
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Europe (PO)
- 30 Jul 2021 Phase-II clinical trials in Atopic dermatitis in USA (PO) (NCT04684485)
- 26 Mar 2021 Phase-II clinical trials in Plaque psoriasis in USA (PO) (NCT04566666)